Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Influence of infection on exacerbations of multiple sclerosis.

Panitch HS.

Ann Neurol. 1994;36 Suppl:S25-8.

PMID:
8017885
2.

Prospective study on the relationship between infections and multiple sclerosis exacerbations.

Buljevac D, Flach HZ, Hop WC, Hijdra D, Laman JD, Savelkoul HF, van Der Meché FG, van Doorn PA, Hintzen RQ.

Brain. 2002 May;125(Pt 5):952-60.

PMID:
11960885
3.

Time-dependent cytokine deviation toward the Th2 side in Japanese multiple sclerosis patients with interferon beta-1b.

Ochi H, Feng-Jun M, Osoegawa M, Minohara M, Murai H, Taniwaki T, Kira J.

J Neurol Sci. 2004 Jul 15;222(1-2):65-73.

PMID:
15240198
4.
5.

Rationale for early treatment with interferon beta-1a in relapsing-remitting multiple sclerosis.

Munschauer FE 3rd, Stuart WH.

Clin Ther. 1997 Sep-Oct;19(5):868-82. Review.

PMID:
9385476
6.
7.

Natural killer cells in relapsing-remitting MS: effect of treatment with interferon beta-1B.

Kastrukoff LF, Morgan NG, Zecchini D, White R, Petkau AJ, Satoh J, Paty DW.

Neurology. 1999 Jan 15;52(2):351-9.

PMID:
9932956
9.

Lowered yields of virus-induced interferon production in leukocyte cultures and risk of recurrent respiratory infections in children.

Pitkäranta A, Nokso-Koivisto J, Jäntti V, Takala A, Kilpi T, Hovi T.

J Clin Virol. 1999 Dec;14(3):199-205.

PMID:
10614857
10.

[Interferon-beta 1a in relapsing-remitting multiple sclerosis. First report of a Mexican population].

León C, Violante A, Arriada N, Santana HR, Corona T.

Rev Neurol. 2000 Dec 1-15;31(11):1019-22. Spanish.

PMID:
11190865
12.

Monthly ambient sunlight, infections and relapse rates in multiple sclerosis.

Tremlett H, van der Mei IA, Pittas F, Blizzard L, Paley G, Mesaros D, Woodbaker R, Nunez M, Dwyer T, Taylor BV, Ponsonby AL.

Neuroepidemiology. 2008;31(4):271-9. doi: 10.1159/000166602. Epub 2008 Oct 30.

PMID:
18971584
13.

Interferon alpha treatment of relapsing-remitting multiple sclerosis: long-term study of the correlations between clinical and magnetic resonance imaging results and effects on the immune function.

Durelli L, Bongioanni MR, Cavallo R, Ferrero B, Ferri R, Verdun E, Bradac GB, Riva A, Geuna M, Bergamini L, et al.

Mult Scler. 1995;1 Suppl 1:S32-7.

PMID:
9345396
14.

Early treatment trials with interferon beta in multiple sclerosis.

Panitch HS.

Mult Scler. 1995;1 Suppl 1:S17-21. Review.

PMID:
9345392
15.

[Tuberculosis in compromised hosts].

[No authors listed]

Kekkaku. 2003 Nov;78(11):717-22. Japanese.

PMID:
14672050
16.

High-dose, frequently administered interferon beta therapy for relapsing-remitting multiple sclerosis must be maintained over the long term: the interferon beta dose-reduction study.

Barbero P, Verdun E, Bergui M, Pipieri A, Clerico M, Cucci A, Ricci A, Bergamasco B, Durelli L.

J Neurol Sci. 2004 Jul 15;222(1-2):13-9.

PMID:
15240190
17.

[Clinical assessment of the course of relapsing-remitting multiple sclerosis in patients treated with interferon beta].

Pokryszko-Dragan A, Bilińska M, Gruszka E, Dubik-Jezierzańska M.

Pol Merkur Lekarski. 2005 Nov;19(113):654-8. Polish.

PMID:
16498805
18.

Epidemiology of documented viral respiratory infections and acute otitis media in a cohort of children followed from two to twenty-four months of age.

Vesa S, Kleemola M, Blomqvist S, Takala A, Kilpi T, Hovi T.

Pediatr Infect Dis J. 2001 Jun;20(6):574-81.

PMID:
11419498
19.

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Fischer JS, Goodkin DE, Granger CV, Simon JH, Alam JJ, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munschauer FE 3rd, Priore RL, Pullicino PM, Scherokman BJ, Whitham RH, et al.

Ann Neurol. 1996 Mar;39(3):285-94. Erratum in: Ann Neurol 1996 Sep;40(3):480.

PMID:
8602746
20.

Supplemental Content

Support Center